These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 443976)
1. Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin. Myers TJ; Steinberg WM; Rickles FR Arch Intern Med; 1979 Jun; 139(6):695-8. PubMed ID: 443976 [TBL] [Abstract][Full Text] [Related]
2. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481 [TBL] [Abstract][Full Text] [Related]
3. Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report. Das S; Karachiwala H; Cherian SV; Garcha AS; Jasti S; Gajra A Blood Coagul Fibrinolysis; 2011 Dec; 22(8):746-8. PubMed ID: 21885951 [TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of the control of antiplatelet therapy through platelet aggregation rate on polycythemia vera associated with thrombocytosis and erythromelalgia]. Kurihara A; Kobayashi I; Tamura K Rinsho Ketsueki; 1989 Jan; 30(1):99-104. PubMed ID: 2716205 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry. Robier C; Neubauer M; Sternad H; Quehenberger F; Rainer F; Neumeister P Thromb Res; 2010 Sep; 126(3):232-7. PubMed ID: 20630570 [TBL] [Abstract][Full Text] [Related]
6. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Landolfi R; Marchioli R Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206 [TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [TBL] [Abstract][Full Text] [Related]
8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T; Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279 [TBL] [Abstract][Full Text] [Related]
9. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Tartaglia AP; Goldberg JD; Berk PD; Wasserman LR Semin Hematol; 1986 Jul; 23(3):172-6. PubMed ID: 3749927 [No Abstract] [Full Text] [Related]
10. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569 [TBL] [Abstract][Full Text] [Related]
11. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Landolfi R; Di Gennaro L; Novarese L; Patrono C Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279 [TBL] [Abstract][Full Text] [Related]
12. The haematocrit and platelet target in polycythemia vera. Di Nisio M; Barbui T; Di Gennaro L; Borrelli G; Finazzi G; Landolfi R; Leone G; Marfisi R; Porreca E; Ruggeri M; Rutjes AW; Tognoni G; Vannucchi AM; Marchioli R; Br J Haematol; 2007 Jan; 136(2):249-59. PubMed ID: 17156406 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of acylpyrin, curantyl and ticlid on some platelet functions in patients with polycythemia vera. Indrák K; Kapustová M; Hrcková Y; Kubis M; Scudla V; Jezdinský J Acta Univ Palacki Olomuc Fac Med; 1985; 111():331-52. PubMed ID: 2949515 [No Abstract] [Full Text] [Related]
15. Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. Bachleitner-Hofmann T; Grumbeck E; Gisslinger H Thromb Res; 2003; 112(4):229-32. PubMed ID: 14987916 [TBL] [Abstract][Full Text] [Related]
16. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Finazzi G; Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715 [TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Elliott MA; Tefferi A Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701 [TBL] [Abstract][Full Text] [Related]
18. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia. Michiels JJ; Berneman Z; Schroyens W; van Urk H Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947 [TBL] [Abstract][Full Text] [Related]
19. Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10. Friess D; Lämmle B; Alberio L Hamostaseologie; 2003 Aug; 23(3):138-43. PubMed ID: 12923585 [TBL] [Abstract][Full Text] [Related]
20. Risk factors and prevention of vascular complications in polycythemia vera. Barbui T; Finazzi G Semin Thromb Hemost; 1997; 23(5):455-61. PubMed ID: 9387204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]